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Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated nuclear receptors controlling many impor-
tant physiological processes, including energy homeosta-
sis, lipid, and glucose metabolism, inﬂammation, as well as
cell proliferation and diﬀerentiation. PPARs and their het-
erodimeric partner (retinoid X receptor, RXR) have been
foundinearlyembryo,developingfetus,andinvariouscom-
partments of the reproductive system (hypothalamus, pitu-
itary gland, ovary, uterus, and testis) of many species (birds,
ﬁshes, mammals such as rodents, cattle, pigs, and humans)
[1]. The reviews in this special issue paint a broad picture of
the potential role of the PPAR-RXR system in the reproduc-
tive axis. They also raise new questions about the biological
actionsofthePPAR-RXRsysteminreproductionanditspos-
sible manipulation in treatments of fertility disorders (due to
problems with energy metabolism, or speciﬁc diseases).
Over the last 10 years, a number of studies in vivo and
in vitro have strongly suggested that these nuclear recep-
tors might play an important role from gametogenesis to
parturition, including gestation and the links mother/fetus
[2]. Thus, PPARs are expressed in the testis where lipid
metabolism and specially the β-oxidation of fatty acids are
important for testicular functions (steroids synthesis, lipid
composition of the sperm, etc.). In addition, some testicular
toxicants such as phthalates bind to PPARα and PPARγ and
modify their activities. In female, invalidation of PPARγ in
themouseovary[3]leadstoadecreaseinfecundityprobably
due to a drop in the production of sexual steroids. Mice null
for PPARβ/δ,P P A R γ,o rR X R α [4–6] display alterations in
the attachment of embryos to the endometrium and/or pla-
centa development and function. During the labor, mRNA
expression of cyclooxygenase-2, an inducer of contractions
of the myometrium and a PPAR target gene, is increased in
fetal membranes when the PPARα and γ expression drops at
the start of parturition. After birth, PPARs continue to play
a role in the relation mother/neonates through the mam-
mary gland functions. Indeed, in transgenic mice, a consti-
tutive activation of PPARα in mammary gland alters its de-
velopment and the lactation leading to mortality of neonates
[7]. Furthermore, mice with a deletion of PPARγ in mam-
mary gland produce a “toxic milk” containing elevated levels
of inﬂammatory lipids. Despite these strong phenotypes, the
mechanisms of action of these receptors remain unclear in
the control of fertility and further investigations are needed
to better use them in medical treatments.
In the future, these drugs might also be used in a large
spectrum of treatments targeting reproduction such as im-
provement of follicular development, in vitro fertilization,
certain complications of pregnancy, and sex hormone-
sensitive cancers aﬀecting the reproductive tissues, includ-
ing breast, prostate, ovary, or cancers aﬀecting pituitary
cells (pituitary adenomas). For example, new generation of
pharmacological drugs targeting these receptors are already
in clinical use or are undergoing testing for use as ther-
apeutic agents. Synthetic molecules (glitazone molecules,
which bind to PPARα, or glitazar molecules, which bind to
PPARα/PPARγ), currently being tested in clinical studies,
may prove particularly useful for the treatment of certain
typesofinfertilityassociatedwithmetabolismdisorderssuch
as insulinoresistance in polycystic ovary syndrome (PCOS)
[8]. The therapeutical treatment in women with pregnancy-
speciﬁc diseases could be also changed. Women with severe
preeclampsia have a reduction in serum levels of PPAR ac-
tivating lipids several weeks before the onset of symptoms.
The use of PPAR ligands might be proposed to ameliorate
the disorders associated with preeclampsia such as hyperten-
sion and inﬂammation. Moreover, the rate of success of in
vitrofertilization(IVF)couldbeimprovedinthenextdecade2 PPAR Research
by addition in the culture media of PPARβ/δ ligands. Recent
studies have shown that the development and implantation
of IVF embryos may be augmented by supplementing cul-
ture media with PGI2 analogs, a synthetic PPARβ/δ ligand,
or retinoic acid [9]. Of note, in all these examples, potential
long-term adverse eﬀects are unknown, and more data need
to be acquired to consider these drugs “safe” during preg-
nancy.
Finally, in this issue, we report the putative functions of
PPARs and RXRs in gonads, placenta, and embryo and we
will discuss the possible role of PPARs as mediators of envi-
ronmental toxicity for reproductive function.
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